J
Jiwei Liu
Researcher at Dalian Medical University
Publications - 34
Citations - 5103
Jiwei Liu is an academic researcher from Dalian Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 8 publications receiving 4328 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).
Lu Si,Xiaoshi Zhang,Yongqian Shu,Hongming Pan,Di Wu,Jiwei Liu,Fang Lou,Lili Mao,Xuan Wang,Xizhi Wen,Yanhong Gu,Lingjun Zhu,Shijie Lan,Xin Cai,Scott J. Diede,Yu Zhou,Jun Ge,Jianfeng Li,Haiyan Wu,Jun Guo +19 more
TL;DR: Pembrolizumab was well tolerated and provided clinically meaningful antitumor activity as second-line therapy in Chinese patients with advanced melanoma and two deaths occurred that were unrelated to treatment.
Journal ArticleDOI
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Cheng,Hui-fang Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Fei Liu,Yong Jiang,Chuan Gu +21 more
TL;DR: Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor as discussed by the authors , which is a new potential treatment option for this population.
Journal ArticleDOI
USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma
Zhen Ning,Xin Guo,Xiaolong Liu,Chang Lu,Aman Wang,Xiaolin Wang,Wen Wang,Huan Chen,Wangshu Qin,Xinyu Liu,Lina Zhou,Chi Ma,Jian Du,Zhikun Lin,Haifeng Luo,Wuxiyar Otkur,Huan Qi,Di Chen,Tian Xia,Jiwei Liu,Guang Tan,Guowang Xu,Hai-long Piao +22 more
TL;DR: In this article , the ubiquitin-specific protease 22 (USP22) was identified as a key regulator for de novo fatty acid synthesis, which directly interacts with deubiquitinates and stabilizes peroxisome proliferator-activated receptor gamma (PPARγ) through K48-linked deUBiquitination, and in turn this stabilization increases acetyl-CoA carboxylase (ACC) and ATP citrate lyase (ACLY) expressions.
Journal ArticleDOI
Clinical practice guidelines on cancer-related anemia (2012-2013 Edition)
Yan Sun,Mei Lin Liao,Zhongzhen Guan,Ji Feng Feng,Bing Hu,Cheng Huang,Jin Li,Xian Ling Li,Jiwei Liu,Wen Chao Liu,Xiao Qing Liu,Yun Peng Liu,Shun Lu,You Lu,Jun Ma,Xue Zhen Ma,Shu kui Qin,Yuan Kai Shi,Jianmin Wang,Jie Jun Wang,Yajie Wang,Zhehai Wang,Wang Lin,Yang Yao,Shi Ying Yu,Ming Zhi Zhang,Li Zhang,Jun Yi Zhang,Yiping Zhang,Yue Zhang,Jun Zhu,Yao Wang +31 more